comparemela.com

Latest Breaking News On - Redchip financial communications united states - Page 6 : comparemela.com

Aptorum Group Limited Interview to Air on Bloomberg Television U S on the RedChip Money Report

Aptorum Group Limited Interview to Air on Bloomberg Television U.S. on the RedChip Money Report Regulatory News: Aptorum Group Limited (Nasdaq: APM), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced an interview with President and Executive Director, Mr. Darren Lui, will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, April 24 at 7 p.m. local time across the United States. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time in 73M homes. To view the interview segment, please visit: https://youtu.be/fKbhSBqKAeI

Aptorum Group Limited: Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases

(0) Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ( Aptorum Group or Aptorum ), a clinical-stage biopharmaceutical company, through its affiliate, has entered into a material transfer and option agreement ( Agreement ) with Yale University ( Yale ) to evaluate a group of preclinical stage novel immunomodulators. The novel immunomodulators may potentially target autoimmune and oncology diseases, including but not limited to, rheumatoid arthritis, lupus and sclerosis, as well as a variety of cancers, all subject to further preclinical development and testing. Aptorum also obtained an exclusive option to in-license the novel immunomodulators and its affiliated intellectual property rights including its patent rights and know-how, based on licensing terms pursuant to a binding term sheet incorporated into the Agreement.

Aptorum Group Limited Reports 2020 Fiscal Year End Financial Results and Provides Business Update

Aptorum Group Limited Reports 2020 Fiscal Year End Financial Results and Provides Business Update Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced financial results for the fiscal year ended December 31, 2020, and provided an update on clinical and corporate developments. Mr. Darren Lui, President and Executive Director of Aptorum Group Limited, commented Aptorum s operational plans remain on track. In particular, one of our lead programs, ALS-4 (targeting infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)) has already commenced dosing of the first cohort of human subjects in its Phase I clinical trial as announced in March 2021. With the additional capital raised in October 2020, the Company is also on track to commence validation of our novel liquid biopsy based rapid pathogen i

Aptorum Group Limited: Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

(1) Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ( Aptorum Group or Aptorum ), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced that the company, through its wholly owned subsidiary, Aptorum International Limited, has received clearance from the Public Health Agency of Canada (Health Canada) regarding the Clinical Trial Application (CTA) to commence a Phase 1 study of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA. Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented, The clearance of our CTA application for ALS-4 drug represents a significant milestone for the company and one of a number of targeted strategic goals for 2021. This milestone supports the transition of Aptorum Group to a clinical-stage company and reflects the potential of our scientific rigor and novel approach of our

Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders

Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the Company , Aptorum Group or Aptorum ), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, today announced the results of its 2020 annual general meeting of shareholders, which was held on December 9, 2020, in Hong Kong. At the annual general meeting, the required number of shareholders of the Company: re-elected all of the Company s current directors, namely Mr. Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Mr. Charles Bathurst, Dr. Mirko Scherer, Dr. Justin Wu and Professor Douglas Arner as directors of the Company until the Company s next annual general meeting of shareholders or until their respective successors are duly appointed and qualified; and

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.